MedTrace Logo

Brain Network Dynamics of Depression During Esketamine Treatment

NCT06012916 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a monocentric, observational clinical trial investigating the effect of Esketamine on brain network activity and a belief updating task in people with depression. We investigate the immediate and the long-term effect (approx. 8 weeks) of Esketamine on EEG signals, pupillometry and belief updating and the relation of those effects on depressive symptomatology.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Esketamine nasal spray

This is an observational study. The Esketamine nasal spray is administered by the attending physician during a regular treatment appointment at the Interventional Psychiatry Clinic. Esketamine dosages may range between 28-84mg. The study does not interfere with the individual treatment plan in any way.

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Flavio Frohlich, PhD · University of North Carolina, Chapel Hill

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-03
Primary Completion
2024-08-30
Completion
2024-08-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06012916 on ClinicalTrials.gov